Benutzer: Gast  Login
Titel:

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
von Bubnoff, N; Gorantla, SP; Engh, RA; Oliveira, TM; Thöne, S; Aberg, E; Peschel, C; Duyster, J
Abstract:
Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B. The most common rearrangement is FIP1L1-PDGFRA (FP). The majority of patients with PDGFR-rearranged myeloproliferation respond to treatment with imatinib. In contrast to BCR-ABL-positive chronic myelogenous leukemia, only few cases of imatinib resistance and mutations of the FP kinase domain have been described so far. We hypothesized that the number of critical residues mediating imatinib resistan...     »
Zeitschriftentitel:
Oncogene
Jahr:
2011
Band / Volume:
30
Heft / Issue:
8
Seitenangaben Beitrag:
933-43
Sprache:
eng
Volltext / DOI:
doi:10.1038/onc.2010.476
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/20972453
Print-ISSN:
0950-9232
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX